Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Pushing the envelope—nonmyeloablative and reduced intensity preparative regimens for allogeneic hematopoietic transplantation

Bone Marrow Transplantation volume 50, pages 1157–1167 (2015)Cite this article

Subjects

Abstract

Allogeneic hematopoietic cell transplantation (HCT) was originally developed to allow delivery of myeloablative doses of chemotherapy and radiotherapy. With better understanding of disease pathophysiology, the graft vs malignancy (GVM) effect of allogeneic hematopoietic transplantation and toxicities associated with myeloablative conditioning (MAC) regimens, the focus shifted to developing less toxic conditioning regimens to reduce treatment-related morbidity without compromising survival. Although HCT with MAC is preferred to reduced intensity conditioning (RIC) for most patients ⩽60 years with AML/myelodysplastic syndrome and ALL, RIC and nonmyeloablative (NMA) regimens allow HCT for many otherwise ineligible patients. Reduced intensity preparative regimens have produced high rates of PFS for diagnoses, which are highly sensitive to GVM. Relapse of the malignancy is the major cause of treatment failure with RIC/NMA HCT. Incorporation of novel agents like bortezomib or lenalidomide, addition of cellular immunotherapy and use of targeted radiation therapies could further improve outcome. In this review, we discuss commonly used RIC/NMA regimens and promising novel regimens.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Copelan EA . Hematopoietic stem-cell transplantation. N Engl J Med 2006; 354: 1813–1826.

    Article  CAS  PubMed  Google Scholar 

  2. Gale RP, Champlin RE . How does bone-marrow transplantation cure leukaemia? Lancet 1984; 2: 28–30.

    CAS  PubMed  Google Scholar 

  3. Thomas ED . Karnofsky Memorial Lecture. Marrow transplantation for malignant diseases. J Clin Oncol 1983; 1: 517–531.

    CAS  PubMed  Google Scholar 

  4. Vriesendorp HM . Aims of conditioning. Exp Hematol 2003; 31: 844–854.

    PubMed  Google Scholar 

  5. Thomas ED, Lochte HL Jr, Cannon JH, Sahler OD, Ferrebee JW . Supralethal whole body irradiation and isologous marrow transplantation in man. J Clin Invest 1959; 38: 1709–1716.

    CAS  PubMed  PubMed Central  Google Scholar 

  6. Clift RA, Buckner CD, Appelbaum FR, Bearman SI, Petersen FB, Fisher LD et al. Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens. Blood 1990; 76: 1867–1871.

    CAS  PubMed  Google Scholar 

  7. Pino y, Torres JL, Bross DS, Lam WC, Wharam MD, Santos GW et al. Risk factors in interstitial pneumonitis following allogenic bone marrow transplantation. Int J Radiat Oncol Biol Phys 1982; 8: 1301–1307.

    Google Scholar 

  8. Hill-Kayser CE, Plastaras JP, Tochner Z, Glatstein E . TBI during BM and SCT: review of the past, discussion of the present and consideration of future directions. Bone Marrow Transplant 2011; 46: 475–484.

    CAS  PubMed  Google Scholar 

  9. Bensinger WI, Clift R, Martin P, Appelbaum FR, Demirer T, Gooley T et al. Allogeneic peripheral blood stem cell transplantation in patients with advanced hematologic malignancies: a retrospective comparison with marrow transplantation. Blood 1996; 88: 2794–2800.

    CAS  PubMed  Google Scholar 

  10. Hassan M . The role of busulfan in bone marrow transplantation. Med Oncol 1999; 16: 166–176.

    CAS  PubMed  Google Scholar 

  11. Ringden O, Remberger M, Ruutu T, Nikoskelainen J, Volin L, Vindelov L et al. Increased risk of chronic graft-versus-host disease, obstructive bronchiolitis, and alopecia with busulfan versus total body irradiation: long-term results of a randomized trial in allogeneic marrow recipients with leukemia. Nordic Bone Marrow Transplantation Group. Blood 1999; 93: 2196–2201.

    CAS  PubMed  Google Scholar 

  12. Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005; 106: 2912–2919.

    CAS  PubMed  PubMed Central  Google Scholar 

  13. Muffly LS, Kocherginsky M, Stock W, Chu Q, Bishop MR, Godley LA et al. Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients. Haematologica 2014; 99: 1373–1379.

    PubMed  PubMed Central  Google Scholar 

  14. Apperley JF, Mauro FR, Goldman JM, Gregory W, Arthur CK, Hows J et al. Bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: importance of a graft-versus-leukaemia effect. Br J Haematol 1988; 69: 239–245.

    CAS  PubMed  Google Scholar 

  15. Weiden PL, Sullivan KM, Flournoy N, Storb R, Thomas ED . Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 1981; 304: 1529–1533.

    CAS  PubMed  Google Scholar 

  16. Odom LF, August CS, Githens JH, Humbert JR, Morse H, Peakman D et al. Remission of relapsed leukaemia during a graft-versus-host reaction. A "graft-versus-leukaemia reaction" in man? Lancet 1978; 2: 537–540.

    CAS  PubMed  Google Scholar 

  17. Sullivan KM, Weiden PL, Storb R, Witherspoon RP, Fefer A, Fisher L et al. Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood 1989; 73: 1720–1728.

    CAS  PubMed  Google Scholar 

  18. Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555–562.

    CAS  PubMed  Google Scholar 

  19. Porter DL . Allogeneic immunotherapy to optimize the graft-versus-tumor effect: concepts and controversies. Hematology Am Soc Hematol Educ Program 2011; 2011: 292–298.

    PubMed  Google Scholar 

  20. Miller JS, Warren EH, van den Brink MR, Ritz J, Shlomchik WD, Murphy WJ et al. NCI First International Workshop on The Biology, Prevention, and Treatment of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Biology Underlying Recurrence of Malignant Disease following Allogeneic HSCT: Graft-versus-Tumor/Leukemia Reaction. Biol Blood Marrow Transplant 2010; 16: 565–586.

    PubMed  PubMed Central  Google Scholar 

  21. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295: 2097–2100.

    Article  CAS  PubMed  Google Scholar 

  22. Cooley S, Weisdorf DJ, Guethlein LA, Klein JP, Wang T, Le CT et al. Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. Blood 2010; 116: 2411–2419.

    CAS  PubMed  PubMed Central  Google Scholar 

  23. Collins RH Jr, Goldstein S, Giralt S, Levine J, Porter D, Drobyski W et al. Donor leukocyte infusions in acute lymphocytic leukemia. Bone Marrow Transplant 2000; 26: 511–516.

    PubMed  Google Scholar 

  24. Kahl C, Storer BE, Sandmaier BM, Mielcarek M, Maris MB, Blume KG et al. Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood 2007; 110: 2744–2748.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. McSweeney PA, Storb R . Mixed chimerism: preclinical studies and clinical applications. Biol Blood Marrow Transplant 1999; 5: 192–203.

    CAS  PubMed  Google Scholar 

  26. McClune BL, Weisdorf DJ . Reduced-intensity conditioning allogeneic stem cell transplantation for older adults: is it the standard of care? Curr Opin Hematol 2010; 17: 133–138.

    PubMed  Google Scholar 

  27. Alyea EP, Kim HT, Ho V, Cutler C, Gribben J, DeAngelo DJ et al. Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood 2005; 105: 1810–1814.

    CAS  PubMed  Google Scholar 

  28. Diaconescu R, Flowers CR, Storer B, Sorror ML, Maris MB, Maloney DG et al. Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors. Blood 2004; 104: 1550–1558.

    CAS  PubMed  Google Scholar 

  29. Belkacemi Y, Labopin M, Hennequin C, Hoffstetter S, Mungai R, Wygoda M et al. Reduced-intensity conditioning regimen using low-dose total body irradiation before allogeneic transplant for hematologic malignancies: Experience from the European Group for Blood and Marrow Transplantation. Int J Radiat Oncol Biol Phys 2007; 67: 544–551.

    PubMed  Google Scholar 

  30. Niederwieser D, Maris M, Shizuru JA, Petersdorf E, Hegenbart U, Sandmaier BM et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood 2003; 101: 1620–1629.

    CAS  PubMed  Google Scholar 

  31. Saito T, Kanda Y, Kami M, Kato K, Shoji N, Kanai S et al. Therapeutic potential of a reduced-intensity preparative regimen for allogeneic transplantation with cladribine, busulfan, and antithymocyte globulin against advanced/refractory acute leukemia/lymphoma. Clin Cancer Res 2002; 8: 1014–1020.

    CAS  PubMed  Google Scholar 

  32. Giralt S, Ballen K, Rizzo D, Bacigalupo A, Horowitz M, Pasquini M et al. Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transplant 2009; 15: 367–369.

    PubMed  PubMed Central  Google Scholar 

  33. Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant 2009; 15: 1628–1633.

    PubMed  PubMed Central  Google Scholar 

  34. Barrett J, Childs R . Non-myeloablative stem cell transplants. Br J Haematol 2000; 111: 6–17.

    CAS  PubMed  Google Scholar 

  35. Little MT, Storb R . The future of allogeneic hematopoietic stem cell transplantation: minimizing pain, maximizing gain. J Clin Invest 2000; 105: 1679–1681.

    CAS  PubMed  PubMed Central  Google Scholar 

  36. Craddock C . Nonmyeloablative stem cell transplants. Curr Opin Hematol 1999; 6: 383–387.

    CAS  PubMed  Google Scholar 

  37. Champlin R, Khouri I, Shimoni A, Gajewski J, Kornblau S, Molldrem J et al. Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy. Br J Haematol 2000; 111: 18–29.

    CAS  PubMed  Google Scholar 

  38. Champlin R, Khouri I, Kornblau S, Molldrem J, Giralt S . Reinventing bone marrow transplantation: reducing toxicity using nonmyeloablative, preparative regimens and induction of graft-versus-malignancy. Curr Opin Oncol 1999; 11: 87–95.

    CAS  PubMed  Google Scholar 

  39. Lekakis L, de Lima M . Reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia. Expert Rev Anticancer Ther 2008; 8: 785–798.

    PubMed  Google Scholar 

  40. Lekakis L, de Padua Silva L, de Lima M . Novel preparative regimens in hematopoietic stem cell transplantation. Curr Pharm Des 2008; 14: 1923–1935.

    CAS  PubMed  Google Scholar 

  41. Alchalby H, Kroger N . Reduced-intensity conditioning followed by allogeneic hematopoietic stem cell transplantation in myelofibrosis. Curr Hematol Malig Rep 2010; 5: 53–61.

    PubMed  Google Scholar 

  42. Couriel DR, Saliba RM, Giralt S, Khouri I, Andersson B, de Lima M et al. Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation. Biol Blood Marrow Transplant 2004; 10: 178–185.

    PubMed  Google Scholar 

  43. Ferrara JL, Deeg HJ . Graft-versus-host disease. N Engl J Med 1991; 324: 667–674.

    CAS  PubMed  Google Scholar 

  44. Soiffer RJ, Lerademacher J, Ho V, Kan F, Artz A, Champlin RE et al. Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Blood 2011; 117: 6963–6970.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Martino R, Caballero MD, Canals C, San Miguel J, Sierra J, Rovira M et al. Reduced-intensity conditioning reduces the risk of severe infections after allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant 2001; 28: 341–347.

    CAS  PubMed  Google Scholar 

  46. Bornhauser M, Kienast J, Trenschel R, Burchert A, Hegenbart U, Stadler M et al. Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial. Lancet Oncol 2012; 13: 1035–1044.

    PubMed  Google Scholar 

  47. Koreth J, Schlenk R, Kopecky KJ, Honda S, Sierra J, Djulbegovic BJ et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA 2009; 301: 2349–2361.

    CAS  PubMed  PubMed Central  Google Scholar 

  48. Holowiecki J . Indications for hematopoietic stem cell transplantation. Polskie Archiwum Medycyny Wewnetrznej 2008; 118: 658–663.

    PubMed  Google Scholar 

  49. Pasquini MCWZ Current use and outcome of hematopoietic stem cell transplantation. In: CIBMTR Summary Slides, 2012.

  50. Farag SS, Maharry K, Zhang MJ, Perez WS, George SL, Mrozek K et al. Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients age 60-70 years with acute myelogenous leukemia in first remission. Biol Blood Marrow Transplant 2011; 17: 1796–1803.

    PubMed  Google Scholar 

  51. McClune BL, Weisdorf DJ, Pedersen TL, Tunes da Silva G, Tallman MS, Sierra J et al. Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. J Clin Oncol 2010; 28: 1878–1887.

    PubMed  PubMed Central  Google Scholar 

  52. van Besien K, Artz A, Smith S, Cao D, Rich S, Godley L et al. Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol 2005; 23: 5728–5738.

    CAS  PubMed  Google Scholar 

  53. Wong R, Giralt SA, Martin T, Couriel DR, Anagnostopoulos A, Hosing C et al. Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years. Blood 2003; 102: 3052–3059.

    CAS  PubMed  Google Scholar 

  54. Taussig DC, Davies AJ, Cavenagh JD, Oakervee H, Syndercombe-Court D, Kelsey S et al. Durable remissions of myelodysplastic syndrome and acute myeloid leukemia after reduced-intensity allografting. J Clin Oncol 2003; 21: 3060–3065.

    CAS  PubMed  Google Scholar 

  55. Alatrash G, de Lima M, Hamerschlak N, Pelosini M, Wang X, Xiao L et al. Myeloablative reduced-toxicity i.v. busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth decades of life. Biol Blood Marrow Transplant 2011; 17: 1490–1496.

    CAS  PubMed  PubMed Central  Google Scholar 

  56. Nakamura R, Rodriguez R, Palmer J, Stein A, Naing A, Tsai N et al. Reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation with fludarabine and melphalan is associated with durable disease control in myelodysplastic syndrome. Bone Marrow Transplant 2007; 40: 843–850.

    CAS  PubMed  Google Scholar 

  57. Blaise DP, Michel Boiron J, Faucher C, Mohty M, Bay JO, Bardoux VJ et al. Reduced intensity conditioning prior to allogeneic stem cell transplantation for patients with acute myeloblastic leukemia as a first-line treatment. Cancer 2005; 104: 1931–1938.

    CAS  PubMed  Google Scholar 

  58. Grigg AP, Gibson J, Bardy PG, Reynolds J, Shuttleworth P, Koelmeyer RL et al. A prospective multicenter trial of peripheral blood stem cell sibling allografts for acute myeloid leukemia in first complete remission using fludarabine-cyclophosphamide reduced intensity conditioning. Biol Blood Marrow Transplant 2007; 13: 560–567.

    CAS  PubMed  Google Scholar 

  59. Valcarcel D, Martino R, Caballero D, Martin J, Ferra C, Nieto JB et al. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival. J Clin Oncol 2008; 26: 577–584.

    CAS  PubMed  Google Scholar 

  60. Kohrt HE, Turnbull BB, Heydari K, Shizuru JA, Laport GG, Miklos DB et al. TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors. Blood 2009; 114: 1099–1109.

    CAS  PubMed  PubMed Central  Google Scholar 

  61. Mohty M, de Lavallade H, Ladaique P, Faucher C, Vey N, Coso D et al. The role of reduced intensity conditioning allogeneic stem cell transplantation in patients with acute myeloid leukemia: a donor vs no donor comparison. Leukemia 2005; 19: 916–920.

    CAS  PubMed  Google Scholar 

  62. Hegenbart U, Niederwieser D, Sandmaier BM, Maris MB, Shizuru JA, Greinix H et al. Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors. J Clin Oncol 2006; 24: 444–453.

    CAS  PubMed  Google Scholar 

  63. Martino R, Iacobelli S, Brand R, Jansen T, van Biezen A, Finke J et al. Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes. Blood 2006; 108: 836–846.

    CAS  PubMed  Google Scholar 

  64. Luger SM, Ringden O, Zhang MJ, Perez WS, Bishop MR, Bornhauser M et al. Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS. Bone Marrow Transplant 2012; 47: 203–211.

    CAS  PubMed  Google Scholar 

  65. Scott BL, Sandmaier BM, Storer B, Maris MB, Sorror ML, Maloney DG et al. Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis. Leukemia 2006; 20: 128–135.

    CAS  PubMed  Google Scholar 

  66. van Besien K, Kunavakkam R, Rondon G, De Lima M, Artz A, Oran B et al. Fludarabine-melphalan conditioning for AML and MDS: alemtuzumab reduces acute and chronic GVHD without affecting long-term outcomes. Biol Blood Marrow Transplant 2009; 15: 610–617.

    CAS  PubMed  PubMed Central  Google Scholar 

  67. Alyea EP, Kim HT, Ho V, Cutler C, DeAngelo DJ, Stone R et al. Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome. Biol Blood Marrow Transplant 2006; 12: 1047–1055.

    PubMed  Google Scholar 

  68. Ringden O, Labopin M, Ehninger G, Niederwieser D, Olsson R, Basara N et al. Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia. J Clin Oncol 2009; 27: 4570–4577.

    PubMed  Google Scholar 

  69. Shimoni A, Hardan I, Shem-Tov N, Yeshurun M, Yerushalmi R, Avigdor A et al. Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity. Leukemia 2006; 20: 322–328.

    CAS  PubMed  Google Scholar 

  70. Flynn CM, Hirsch B, Defor T, Barker JN, Miller JS, Wagner JE et al. Reduced intensity compared with high dose conditioning for allotransplantation in acute myeloid leukemia and myelodysplastic syndrome: a comparative clinical analysis. Am J Hematol 2007; 82: 867–872.

    PubMed  Google Scholar 

  71. Aoudjhane M, Labopin M, Gorin NC, Shimoni A, Ruutu T, Kolb HJ et al. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Leukemia 2005; 19: 2304–2312.

    CAS  PubMed  Google Scholar 

  72. de Lima M, Anagnostopoulos A, Munsell M, Shahjahan M, Ueno N, Ippoliti C et al. Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood 2004; 104: 865–872.

    CAS  PubMed  Google Scholar 

  73. Gyurkocza B, Storb R, Storer BE, Chauncey TR, Lange T, Shizuru JA et al. Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia. J Clin Oncol 2010; 28: 2859–2867.

    PubMed  PubMed Central  Google Scholar 

  74. Kantarjian H, Thomas D, O'Brien S, Cortes J, Giles F, Jeha S et al. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer 2004; 101: 2788–2801.

    CAS  PubMed  Google Scholar 

  75. Takeuchi J, Kyo T, Naito K, Sao H, Takahashi M, Miyawaki S et al. Induction therapy by frequent administration of doxorubicin with four other drugs, followed by intensive consolidation and maintenance therapy for adult acute lymphoblastic leukemia: the JALSG-ALL93 study. Leukemia 2002; 16: 1259–1266.

    CAS  PubMed  Google Scholar 

  76. Goldstone AH, Richards SM, Lazarus HM, Tallman MS, Buck G, Fielding AK et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood 2008; 111: 1827–1833.

    CAS  PubMed  Google Scholar 

  77. Martino R, Giralt S, Caballero MD, Mackinnon S, Corradini P, Fernandez-Aviles F et al. Allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning in acute lymphoblastic leukemia: a feasibility study. Haematologica 2003; 88: 555–560.

    PubMed  Google Scholar 

  78. Hamaki T, Kami M, Kanda Y, Yuji K, Inamoto Y, Kishi Y et al. Reduced-intensity stem-cell transplantation for adult acute lymphoblastic leukemia: a retrospective study of 33 patients. Bone Marrow Transplant 2005; 35: 549–556.

    CAS  PubMed  Google Scholar 

  79. Mohty M, Labopin M, Tabrizzi R, Theorin N, Fauser AA, Rambaldi A et al. Reduced intensity conditioning allogeneic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation. Haematologica 2008; 93: 303–306.

    PubMed  Google Scholar 

  80. Bachanova V, Verneris MR, DeFor T, Brunstein CG, Weisdorf DJ . Prolonged survival in adults with acute lymphoblastic leukemia after reduced-intensity conditioning with cord blood or sibling donor transplantation. Blood 2009; 113: 2902–2905.

    CAS  PubMed  Google Scholar 

  81. Ram R, Storb R, Sandmaier BM, Maloney DG, Woolfrey A, Flowers ME et al. Non-myeloablative conditioning with allogeneic hematopoietic cell transplantation for the treatment of high-risk acute lymphoblastic leukemia. Haematologica 2011; 96: 1113–1120.

    PubMed  PubMed Central  Google Scholar 

  82. Stein AS, Palmer JM, O'Donnell MR, Kogut NM, Spielberger RT, Slovak ML et al. Reduced-intensity conditioning followed by peripheral blood stem cell transplantation for adult patients with high-risk acute lymphoblastic leukemia. Biol Blood Marrow Transplant 2009; 15: 1407–1414.

    PubMed  PubMed Central  Google Scholar 

  83. Cho BS, Lee S, Kim YJ, Chung NG, Eom KS, Kim HJ et al. Reduced-intensity conditioning allogeneic stem cell transplantation is a potential therapeutic approach for adults with high-risk acute lymphoblastic leukemia in remission: results of a prospective phase 2 study. Leukemia 2009; 23: 1763–1770.

    CAS  PubMed  Google Scholar 

  84. Arnold R, Massenkeil G, Bornhauser M, Ehninger G, Beelen DW, Fauser AA et al. Nonmyeloablative stem cell transplantation in adults with high-risk ALL may be effective in early but not in advanced disease. Leukemia 2002; 16: 2423–2428.

    CAS  PubMed  Google Scholar 

  85. Eom K-S, Shin S-H, Yoon J-H, Yahng S-A, Lee S-E, Cho B-S et al. Comparable long-term outcomes after reduced-intensity conditioning versus myeloablative conditioning allogeneic stem cell transplantation for adult high-risk acute lymphoblastic leukemia in complete remission. Am J Hematol 2013; 88: 634–641.

    CAS  PubMed  Google Scholar 

  86. Marks DI, Wang T, Pérez WS, Antin JH, Copelan E, Gale RP et al. The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome–negative acute lymphoblastic leukemia in first and second complete remission. Blood 2010; 116: 366–374.

    CAS  PubMed  PubMed Central  Google Scholar 

  87. Mohty M, Labopin M, Volin L, Gratwohl A, Socie G, Esteve J et al. Reduced-intensity versus conventional myeloablative conditioning allogeneic stem cell transplantation for patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation. Blood 2010; 116: 4439–4443.

    CAS  PubMed  Google Scholar 

  88. Bachanova V, Marks DI, Zhang MJ, Wang H, de Lima M, Aljurf MD et al. Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual disease. Leukemia 2013; 28: 658–665.

    PubMed  PubMed Central  Google Scholar 

  89. Das M, Saikia TK, Advani SH, Parikh PM, Tawde S . Use of a reduced-intensity conditioning regimen for allogeneic transplantation in patients with chronic myeloid leukemia. Bone Marrow Transplant 2003; 32: 125–129.

    CAS  PubMed  Google Scholar 

  90. Crawley C, Szydlo R, Lalancette M, Bacigalupo A, Lange A, Brune M et al. Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. Blood 2005; 106: 2969–2976.

    CAS  PubMed  Google Scholar 

  91. Luo Y, Lai XY, Tan YM, Shi JM, Zhao YM, Han XY et al. Reduced-intensity allogeneic transplantation combined with imatinib mesylate for chronic myeloid leukemia in first chronic phase. Leukemia 2009; 23: 1171–1174.

    CAS  PubMed  Google Scholar 

  92. Warlick E, Ahn KW, Pedersen TL, Artz A, de Lima M, Pulsipher M et al. Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era. Blood 2012; 119: 4083–4090.

    CAS  PubMed  PubMed Central  Google Scholar 

  93. Kebriaei P, Detry MA, Giralt S, Carrasco-Yalan A, Anagnostopoulos A, Couriel D et al. Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia. Blood 2007; 110: 3456–3462.

    CAS  PubMed  Google Scholar 

  94. Topcuoglu P, Arat M, Ozcan M, Arslan O, Ilhan O, Beksac M et al. Case-matched comparison with standard versus reduced intensity conditioning regimen in chronic myeloid leukemia patients. Ann Hematol 2012; 91: 577–586.

    PubMed  Google Scholar 

  95. McSweeney PA, Niederwieser D, Shizuru JA, Sandmaier BM, Molina AJ, Maloney DG et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001; 97: 3390–3400.

    CAS  PubMed  Google Scholar 

  96. Khouri IF, Keating M, Korbling M, Przepiorka D, Anderlini P, O'Brien S et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998; 16: 2817–2824.

    CAS  PubMed  Google Scholar 

  97. Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756–763.

    CAS  PubMed  Google Scholar 

  98. Ben-Bassat I, Raanani P, Gale RP . Graft-versus-leukemia in chronic lymphocytic leukemia. Bone Marrow Transplant 2007; 39: 441–446.

    CAS  PubMed  Google Scholar 

  99. Pavletic ZS, Arrowsmith ER, Bierman PJ, Goodman SA, Vose JM, Tarantolo SR et al. Outcome of allogeneic stem cell transplantation for B cell chronic lymphocytic leukemia. Bone Marrow Transplant 2000; 25: 717–722.

    CAS  PubMed  Google Scholar 

  100. Mattsson J, Uzunel M, Remberger M, Ljungman P, Kimby E, Ringden O et al. Minimal residual disease is common after allogeneic stem cell transplantation in patients with B cell chronic lymphocytic leukemia and may be controlled by graft-versus-host disease. Leukemia 2000; 14: 247–254.

    CAS  PubMed  Google Scholar 

  101. Mehta J, Powles R, Singhal S, Iveson T, Treleaven J, Catovsky D et al. Clinical and hematologic response of chronic lymphocytic and prolymphocytic leukemia persisting after allogeneic bone marrow transplantation with the onset of acute graft-versus-host disease: possible role of graft-versus-leukemia. Bone Marrow Transplant 1996; 17: 371–375.

    CAS  PubMed  Google Scholar 

  102. Dreger P . The evolving role of stem cell transplantation in chronic lymphocytic leukemia. Hematol Oncol Clin North Am 2013; 27: 355–369.

    PubMed  Google Scholar 

  103. Sorror ML, Storer BE, Sandmaier BM, Maris M, Shizuru J, Maziarz R et al. Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. J Clin Oncol 2008; 26: 4912–4920.

    PubMed  PubMed Central  Google Scholar 

  104. Khouri IF, Bassett R, Poindexter N, O'Brien S, Bueso-Ramos CE, Hsu Y et al. Nonmyeloablative allogeneic stem cell transplantation in relapsed/refractory chronic lymphocytic leukemia: long-term follow-up, prognostic factors, and effect of human leukocyte histocompatibility antigen subtype on outcome. Cancer 2011; 117: 4679–4688.

    PubMed  Google Scholar 

  105. Dreger P, Dohner H, Ritgen M, Bottcher S, Busch R, Dietrich S et al. Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial. Blood 2010; 116: 2438–2447.

    CAS  PubMed  Google Scholar 

  106. Michallet M, Sobh M, Morisset S . Rituximab in allogeneic HSCT for advanced chronic lymphocytic leukemia with fludarabine + total body irradiation conditioning: results of a phase II prospective multicenter study (ITAC 02-02). Bone Marrow Transplant 2011; 46: S43–S44.

    Google Scholar 

  107. Peres E, Braun T, Krijanovski O, Khaled Y, Levine JE, Yanik G et al. Reduced intensity versus full myeloablative stem cell transplant for advanced CLL. Bone Marrow Transplant 2009; 44: 579–583.

    CAS  PubMed  Google Scholar 

  108. Brown JR, Kim HT, Armand P, Cutler C, Fisher DC, Ho V et al. Long-term follow-up of reduced-intensity allogeneic stem cell transplantation for chronic lymphocytic leukemia: prognostic model to predict outcome. Leukemia 2013; 27: 362–369.

    CAS  PubMed  Google Scholar 

  109. Giralt S, Aleman A, Anagnostopoulos A, Weber D, Khouri I, Anderlini P et al. Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma. Bone Marrow Transplant 2002; 30: 367–373.

    CAS  PubMed  Google Scholar 

  110. Mohty M, Boiron JM, Damaj G, Michallet AS, Bay JO, Faucher C et al. Graft-versus-myeloma effect following antithymocyte globulin-based reduced intensity conditioning allogeneic stem cell transplantation. Bone Marrow Transplant 2004; 34: 77–84.

    CAS  PubMed  Google Scholar 

  111. Gerull S, Goerner M, Benner A, Hegenbart U, Klein U, Schaefer H et al. Long-term outcome of nonmyeloablative allogeneic transplantation in patients with high-risk multiple myeloma. Bone Marrow Transplant 2005; 36: 963–969.

    CAS  PubMed  Google Scholar 

  112. Kroger N, Sayer HG, Schwerdtfeger R, Kiehl M, Nagler A, Renges H et al. Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality. Blood 2002; 100: 3919–3924.

    CAS  PubMed  Google Scholar 

  113. Crawley C, Iacobelli S, Bjorkstrand B, Apperley JF, Niederwieser D, Gahrton G et al. Reduced-intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning. Blood 2007; 109: 3588–3594.

    CAS  PubMed  Google Scholar 

  114. Koreth J, Stevenson KE, Kim HT, Garcia M, Ho VT, Armand P et al. Bortezomib, tacrolimus, and methotrexate for prophylaxis of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation from HLA-mismatched unrelated donors. Blood 2009; 114: 3956–3959.

    CAS  PubMed  PubMed Central  Google Scholar 

  115. Khouri IF, McLaughlin P, Saliba RM, Hosing C, Korbling M, Lee MS et al. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood 2008; 111: 5530–5536.

    CAS  PubMed  PubMed Central  Google Scholar 

  116. Khouri IF, Saliba RM, Erwin WD, Samuels BI, Korbling M, Medeiros LJ et al. Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results. Blood 2012; 119: 6373–6378.

    CAS  PubMed  PubMed Central  Google Scholar 

  117. Piñana JL, Martino R, Gayoso J, Sureda A, de la Serna J, Díez-Martín JL et al. Reduced intensity conditioning HLA identical sibling donor allogeneic stem cell transplantation for patients with follicular lymphoma: long-term follow-up from two prospective multicenter trials. Haematologica 2010; 95: 1176–1182.

    PubMed  PubMed Central  Google Scholar 

  118. Vigouroux S, Michallet M, Porcher R, Attal M, Ades L, Bernard M et al. Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC). Haematologica 2007; 92: 627–634.

    PubMed  Google Scholar 

  119. Cook G, Smith GM, Kirkland K, Lee J, Pearce R, Thomson K et al. Outcome following Reduced-Intensity Allogeneic Stem Cell Transplantation (RIC AlloSCT) for relapsed and refractory mantle cell lymphoma (MCL): a study of the British Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2010; 16: 1419–1427.

    PubMed  Google Scholar 

  120. Rezvani AR, Norasetthada L, Gooley T, Sorror M, Bouvier ME, Sahebi F et al. Non-myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: a multicentre experience. Br J Haematol 2008; 143: 395–403.

    PubMed  PubMed Central  Google Scholar 

  121. Thomson KJ, Morris EC, Bloor A, Cook G, Milligan D, Parker A et al. Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin's lymphoma. J Clin Oncol 2009; 27: 426–432.

    PubMed  Google Scholar 

  122. Sirvent A, Dhedin N, Michallet M, Mounier N, Faucher C, Yakoub-Agha I et al. Low nonrelapse mortality and prolonged long-term survival after reduced-intensity allogeneic stem cell transplantation for relapsed or refractory diffuse large B cell lymphoma: report of the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. Biol Blood Marrow Transplant 2010; 16: 78–85.

    PubMed  Google Scholar 

  123. Hari P, Carreras J, Zhang MJ, Gale RP, Bolwell BJ, Bredeson CN et al. Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning. Biol Blood Marrow Transplant 2008; 14: 236–245.

    PubMed  PubMed Central  Google Scholar 

  124. Hamadani M, Saber W, Ahn KW, Carreras J, Cairo MS, Fenske TS et al. Allogeneic hematopoietic cell transplantation for chemotherapy-unresponsive mantle cell lymphoma: a cohort analysis from the center for international blood and marrow transplant research. Biol Blood Marrow Transplant 2013; 19: 625–631.

    PubMed  PubMed Central  Google Scholar 

  125. Bacher U, Klyuchnikov E, Le-Rademacher J, Carreras J, Armand P, Bishop MR et al. Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity? Blood 2012; 120: 4256–4262.

    CAS  PubMed  PubMed Central  Google Scholar 

  126. Thomson KJ, Morris EC, Milligan D, Parker AN, Hunter AE, Cook G et al. T-cell-depleted reduced-intensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellent long-term survival in patients with multiply relapsed follicular lymphoma. J Clin Oncol 2010; 28: 3695–3700.

    PubMed  Google Scholar 

  127. Shea T, Johnson J, Westervelt P, Farag S, McCarty J, Bashey A et al. Reduced-intensity allogeneic transplantation provides high event-free and overall survival in patients with advanced indolent B cell malignancies: CALGB 109901. Biol Blood Marrow Transplant 2011; 17: 1395–1403.

    PubMed  PubMed Central  Google Scholar 

  128. Hamadani M, Saber W, Ahn KW, Carreras J, Cairo MS, Fenske TS et al. Allogeneic hematopoietic cell transplantation for chemotherapy-unresponsive mantle cell lymphoma: A Cohort Analysis from the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant 2013; 19: 625–631.

    PubMed  PubMed Central  Google Scholar 

  129. Wei W, Valverde R, Korbling M, Turturro F, Gulbis AM, Guillermo-Pacheco M et al. Bfr (bendamustine, fludarabine, rituximab) nonmyeloablative allogeneic conditioning: a novel regimen inducing immunosuppression without myelosuppression. Blood 2013; 122: 541.

    Google Scholar 

  130. Gopal AK, Guthrie KA, Rajendran J, Pagel JM, Oliveira G, Maloney DG et al. (9)(0)Y-Ibritumomab tiuxetan, fludarabine, and TBI-based nonmyeloablative allogeneic transplantation conditioning for patients with persistent high-risk B-cell lymphoma. Blood 2011; 118: 1132–1139.

    CAS  PubMed  PubMed Central  Google Scholar 

  131. Alvarez I, Sureda A, Caballero MD, Urbano-Ispizua A, Ribera JM, Canales M et al. Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed hodgkin lymphoma: results of a spanish prospective cooperative protocol. Biol Blood Marrow Transplant 2006; 12: 172–183.

    PubMed  Google Scholar 

  132. Sureda A, Canals C, Arranz R, Caballero D, Ribera JM, Brune M et al. Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin's lymphoma. Results of the HDR-ALLO study -a prospective clinical trial by the Grupo Espanol de Linfomas/Trasplante de Medula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Haematologica 2012; 97: 310–317.

    PubMed  PubMed Central  Google Scholar 

  133. Sureda A, Robinson S, Canals C, Carella AM, Boogaerts MA, Caballero D et al. Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2008; 26: 455–462.

    CAS  PubMed  Google Scholar 

  134. Anderlini P, Saliba R, Acholonu S, Okoroji GJ, Donato M, Giralt S et al. Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen. Bone Marrow Transplant 2005; 35: 943–951.

    CAS  PubMed  Google Scholar 

  135. Anderlini P, Saliba R, Acholonu S, Giralt SA, Andersson B, Ueno NT et al. Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience. Haematologica 2008; 93: 257–264.

    CAS  PubMed  Google Scholar 

  136. Robinson SP, Sureda A, Canals C, Russell N, Caballero D, Bacigalupo A et al. Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin's lymphoma: identification of prognostic factors predicting outcome. Haematologica 2009; 94: 230–238.

    PubMed  Google Scholar 

  137. Anderlini P, Saliba RM, Ledesma C, Chancoco CM, Alexander T, Alousi A et al. Reduced-intensity conditioning (RIC) and allogeneic stem cell transplantation (allo-SCT) for relapsed/refractory Hodgkin lymphoma (HL) in the Brentuximab Vedotin era: favorable overall and progression-free survival (OS/PFS) with low transplant-related mortality (TRM). Blood 2013; 122: 410.

    Google Scholar 

  138. Giralt S, Thall PF, Khouri I, Wang X, Braunschweig I, Ippolitti C et al. Melphalan and purine analog–containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 2001; 97: 631–637.

    CAS  PubMed  Google Scholar 

  139. Bryant A, Nivison-Smith I, Pillai ES, Kennedy G, Kalff A, Ritchie D et al. Fludarabine Melphalan reduced-intensity conditioning allotransplanation provides similar disease control in lymphoid and myeloid malignancies: analysis of 344 patients. Bone Marrow Transplant 2014; 49: 17–23.

    CAS  PubMed  Google Scholar 

  140. Chakraverty R, Peggs K, Chopra R, Milligan DW, Kottaridis PD, Verfuerth S et al. Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood 2002; 99: 1071–1078.

    CAS  PubMed  Google Scholar 

  141. Hale G, Zhang MJ, Bunjes D, Prentice HG, Spence D, Horowitz MM et al. Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection. Blood 1998; 92: 4581–4590.

    CAS  PubMed  Google Scholar 

  142. Perez-Simon JA, Kottaridis PD, Martino R, Craddock C, Caballero D, Chopra R et al. Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders. Blood 2002; 100: 3121–3127.

    CAS  PubMed  Google Scholar 

  143. Soiffer RJ, LeRademacher J, Ho V, Kan F, Artz A, Champlin RE et al. Impact of immune modulation with anti–T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Blood 2011; 117: 6963–6970.

    CAS  PubMed  PubMed Central  Google Scholar 

  144. Baron F, Labopin M, Niederwieser D, Vigouroux S, Cornelissen JJ, Malm C et al. Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation. Leukemia 2012; 26: 2462–2468.

    CAS  PubMed  Google Scholar 

  145. Gartner F, Hieke S, Finke J, Bertz H . Lowering the alemtuzumab dose in reduced intensity conditioning allogeneic hematopoietic cell transplantation is associated with a favorable early intense natural killer cell recovery. Cytotherapy 2013; 15: 1237–1244.

    PubMed  Google Scholar 

  146. Brunner AM, Kim HT, Coughlin E, Alyea EP 3rd, Armand P, Ballen KK et al. Outcomes in patients age 70 or older undergoing allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Biol Blood Marrow Transplant 2013; 19: 1374–1380.

    PubMed  Google Scholar 

  147. Chen YB, Coughlin E, Kennedy KF, Alyea EP, Armand P, Attar EC et al. Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia. Biol Blood Marrow Transplant 2013; 19: 981–987.

    PubMed  Google Scholar 

  148. Devillier R, Furst S, El-Cheikh J, Castagna L, Harbi S, Granata A et al. Antithymocyte globulin in reduced-intensity conditioning regimen allows a high disease-free survival exempt of long-term chronic graft-versus-host disease. Biol Blood Marrow Transplant 2014; 20: 370–374.

    CAS  PubMed  Google Scholar 

  149. Sorror ML, Sandmaier BM, Storer BE, Franke GN, Laport GG, Chauncey TR et al. Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies. JAMA 2011; 306: 1874–1883.

    CAS  PubMed  PubMed Central  Google Scholar 

  150. Kornblit B, Maloney DG, Storb R, Storek J, Hari P, Vucinic V et al. Fludarabine and 2-Gy TBI is superior to 2 Gy TBI as conditioning for HLA-matched related hematopoietic cell transplantation: a phase III randomized trial. Biol Blood Marrow Transplant 2013; 19: 1340–1347.

    CAS  PubMed  PubMed Central  Google Scholar 

  151. Michallet M, Sobh M, Milpied N, Bay JO, Furst S, Harousseau JL et al. Phase II prospective study of treosulfan-based reduced-intensity conditioning in allogeneic HSCT for hematological malignancies from 10/10 HLA-identical unrelated donor. Ann Hematol 2012; 91: 1289–1297.

    CAS  PubMed  Google Scholar 

  152. Buchholz S, Dammann E, Stadler M, Krauter J, Beutel G, Trummer A et al. Cytoreductive treatment with clofarabine/ara-C combined with reduced-intensity conditioning and allogeneic stem cell transplantation in patients with high-risk, relapsed, or refractory acute myeloid leukemia and advanced myelodysplastic syndrome. Eur J Haematol 2012; 88: 52–60.

    CAS  PubMed  Google Scholar 

  153. Chevallier P, Labopin M, Socie G, Tabrizi R, Furst S, Lioure B et al. Results from a clofarabine-busulfan-containing, reduced-toxicity conditioning regimen prior to allogeneic stem cell transplantation: the phase 2 prospective CLORIC trial. Haematologica 2014; 99: 1486–1491.

    CAS  PubMed  PubMed Central  Google Scholar 

  154. Kirschbaum MH, Stein AS, Popplewell L, Delioukina M, Chen R, Nakamura R et al. A phase I study in adults of clofarabine combined with high-dose melphalan as reduced-intensity conditioning for allogeneic transplantation. Biol Blood Marrow Transplant 2012; 18: 432–440.

    CAS  PubMed  Google Scholar 

  155. Chevallier P, Labopin M, Buchholz S, Ganser A, Ciceri F, Lioure B et al. Clofarabine-containing conditioning regimen for allo-SCT in AML/ALL patients: a survey from the Acute Leukemia Working Party of EBMT. Eur J Haematol 2012; 89: 214–219.

    CAS  PubMed  Google Scholar 

  156. Pagel JM, Gooley TA, Rajendran J, Fisher DR, Wilson WA, Sandmaier BM et al. Allogeneic hematopoietic cell transplantation after conditioning with 131I–anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome. Blood 2009; 114: 5444–5453.

    CAS  PubMed  PubMed Central  Google Scholar 

  157. Ringhoffer M, Blumstein N, Neumaier B, Glatting G, von Harsdorf S, Buchmann I et al. 188Re or 90Y-labelled anti-CD66 antibody as part of a dose-reduced conditioning regimen for patients with acute leukaemia or myelodysplastic syndrome over the age of 55: results of a phase I-II study. Br J Haematol 2005; 130: 604–613.

    CAS  PubMed  Google Scholar 

  158. McDevitt MR, Sgouros G, Finn RD, Humm JL, Jurcic JG, Larson SM et al. Radioimmunotherapy with alpha-emitting nuclides. Eur J Nucl Med 1998; 25: 1341–1351.

    CAS  PubMed  Google Scholar 

  159. Jurcic JG, Rosenblat TL . Targeted alpha-particle immunotherapy for acute myeloid leukemia. Am Soc Clin Oncol Educ Book 2014, e126–e131.

    Google Scholar 

  160. Jurcic JG, Larson SM, Sgouros G, McDevitt MR, Finn RD, Divgi CR et al. Targeted alpha particle immunotherapy for myeloid leukemia. Blood 2002; 100: 1233–1239.

    CAS  PubMed  Google Scholar 

  161. Rosenblat TL, McDevitt MR, Mulford DA, Pandit-Taskar N, Divgi CR, Panageas KS et al. Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia. Clin Cancer Res 2010; 16: 5303–5311.

    CAS  PubMed  PubMed Central  Google Scholar 

  162. Sandmaier BM, Bethge WA, Wilbur DS, Hamlin DK, Santos EB, Brechbiel MW et al. Bismuth 213-labeled anti-CD45 radioimmunoconjugate to condition dogs for nonmyeloablative allogeneic marrow grafts. Blood 2002; 100: 318–326.

    CAS  PubMed  Google Scholar 

  163. Bethge WA, Wilbur DS, Storb R, Hamlin DK, Santos EB, Brechbiel MW et al. Selective T-cell ablation with bismuth-213-labeled anti-TCRalphabeta as nonmyeloablative conditioning for allogeneic canine marrow transplantation. Blood 2003; 101: 5068–5075.

    CAS  PubMed  Google Scholar 

  164. Pagel JM, Kenoyer AL, Back T, Hamlin DK, Wilbur DS, Fisher DR et al. Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft model. Blood 2011; 118: 703–711.

    CAS  PubMed  PubMed Central  Google Scholar 

  165. Sharkey RM, Karacay H, Chang CH, McBride WJ, Horak ID, Goldenberg DM et al. Improved therapy of non-Hodgkin's lymphoma xenografts using radionuclides pretargeted with a new anti-CD20 bispecific antibody. Leukemia 2005; 19: 1064–1069.

    CAS  PubMed  Google Scholar 

  166. Liu G, Dou S, Mardirossian G, He J, Zhang S, Liu X et al. Successful radiotherapy of tumor in pretargeted mice by 188Re-radiolabeled phosphorodiamidate morpholino oligomer, a synthetic DNA analogue. Clin Cancer Res 2006; 12: 4958–4964.

    CAS  PubMed  PubMed Central  Google Scholar 

  167. Chargari C, Vernant JP, Tamburini J, Zefkili S, Fayolle M, Campana F et al. Feasibility of helical tomotherapy for debulking irradiation before stem cell transplantation in malignant lymphoma. Int J Radiat Oncol Biol Phys 2011; 81: 1184–1189.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    S R Pingali & R E Champlin

Authors
  1. S R Pingali
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R E Champlin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R E Champlin.

Ethics declarations

Competing interests

Dr Champlin has had research grant funding from Otsuka, Sanofi and Celgene Corporations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pingali, S., Champlin, R. Pushing the envelope—nonmyeloablative and reduced intensity preparative regimens for allogeneic hematopoietic transplantation. Bone Marrow Transplant 50, 1157–1167 (2015). https://doi.org/10.1038/bmt.2015.61

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2015.61

This article is cited by

Search

Advanced search

Quick links